安永料大型IPO推動第四季香港IPO市場維持增長
安永發表報告指,第三季全球IPO市場集資額創近20年同期最高,集資額增加43%至1,653億美元,交易宗數亦為20年同期第二高,宗數達872宗,增長14%。其中,香港第三季新股集資額大幅增長60%,名列全球第三。
該行指出,有數宗大型IPO即將上市,預計香港IPO市場於2020年第四季度將維持增長勢頭,包括醫療科技、金融科技、供應鏈、物流、教育以及持續發展相關的企業都將來港上市。
安永亞太區上市服務主管合夥人蔡偉榮表示,近期上市的新經濟公司以及未受疫情影響的公司都錄得高估值,對尋求於第四季度完成上市的公司有正面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.